Asia Executives On The Move: EdiGene, Teijin, Astellas
Executive Summary
New round of funding allows EdiGene to hire a clinical development executive from Parexel, Teijin Pharma appoints a president, while Astellas has a new president of pharmaceutical technology.
You may also be interested in...
Invitation Extended: New Chinese Policies Aim To Lure Foreign Pharma Firms
In their latest charm offensive, Chinese regulators issue policies clearly designed to encourage the import of innovative drugs from overseas and better serve foreign drug makers already operating in the country.
China Relaxes Restrictions Amid 'Zero' Severe Shanghai Cases
China is signalling its intention to gradually re-open its borders amid real-world data showing few mild-to-moderate cases progress to severe symptoms. Meanwhile, Pfizer's Paxlovid is seemingly struggling to gain traction amid use guideline changes.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: Genmab confident in CD20xCD3 battle; Alzheimer’s disappointment for Roche; Japan speed bump for Shionogi’s oral COVID antiviral; pharma’s view of psychedelics; and a roundup of key BIO sessions.